Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Efficacy and Safety of Ruxolitinib Cream in Vitiligo (Randomized Withdrawal and Extension)
2020-000987-53Phase 3Completed
- Sponsor
- Incyte
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ruxolitinib in Vitiligo (3 arms), sponsored by Incyte. Primary endpoint: Duration of clinical response. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2020-000987-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000987-53.